News Releases

Showing results filtered by:

December 2015

November 2015

  • NIH Statement on World AIDS Day 2015

    November 30, 2015

    ​When the first cases of what would become known as AIDS were reported in 1981, scientists and physicians did not know the cause and had no therapies to treat those who were infected. Times have changed and today physicians can offer their patients highly effective medicines that work as both treatment and prevention. 

  • NIH Publishes Criteria for Research on Organ Transplantation Between People with HIV Infection

    November 25, 2015

    The U.S. Department of Health and Human Services published safeguards and criteria for research to assess the safety and effectiveness of solid organ transplantation from donors with HIV infection to recipients with HIV infection. 

  • NIH-Sponsored Clinical Trial of Chikungunya Vaccine Opens

    November 24, 2015

    An experimental vaccine to protect against the mosquito-borne illness chikungunya is being tested in a Phase 2 trial sponsored by the National Institutes of Health.

  • NIH Launches Initiative to Develop Long-Acting HIV Treatment and Prevention Tools

    November 18, 2015

    The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, launched a major initiative to advance novel approaches to treat and prevent HIV infections based on broadly neutralizing antibodies (bNAbs)

  • RSV Pediatric Vaccine Candidate Shows Promise in Early Clinical Trial

    November 5, 2015

    Scientists from the National Institute of Allergy and Infectious Diseases and colleagues  have developed a vaccine candidate to protect infants and young children against respiratory syncytial virus that appears to elicit a stronger protective immune response than the previous lead vaccine candidate.

October 2015

  • Short-Term Additional Treatment Reduces Asthma Attacks in Inner-City Children During Fall

    October 27, 2015

    Adding the drug omalizumab to ongoing guidelines-based asthma therapy for a targeted four-month period beginning just before the start of school reduced the number of autumn asthma attacks, or exacerbations, in inner-city children. 

  • NIH-Funded Study Reveals Why Malaria Vaccine Only Partially Protected Children, Infants

    October 22, 2015

    Using new, highly sensitive genomic sequencing technology, an international team of researchers has found new biological evidence to help explain why the malaria vaccine candidate RTS,S/AS01 (called RTS,S) provided only moderate protection among vaccinated children during clinical testing.

  • Immune Responses Provide Clues for HIV Vaccine Development

    October 21, 2015

    Recent research has yielded new information about immune responses associated with—and potentially responsible for—protection from HIV infection, providing leads for new strategies to develop an HIV vaccine. 

  • NIH Study Reveals Risk of Drug-Resistant Malaria Spreading to Africa

    October 20, 2015

    Drug-resistant forms of Plasmodium falciparum can infect the type of mosquito that is the main transmitter of malaria in Africa. The discovery suggests Africa is more at risk for drug-resistant malaria infections than previously thought, which could further compromise efforts to prevent and eliminate the disease.

  • HIV Cure Research: NIH Scientists Create Two-Headed Protein to Deplete HIV Reservoir

    October 20, 2015

    Scientists at the National Institutes of Health have created a protein that awakens resting immune cells infected with HIV and facilitates their destruction in laboratory studies.

  • Experimental Aerosol TB Vaccine Protects Monkeys, NIH-Funded Researchers Find

    October 16, 2015

    Researchers funded by the National Institute of Allergy and Infectious Diseases have developed an investigational aerosol tuberculosis vaccine that induced potent immune responses in a small number of rhesus macaques and protected them against pulmonary infection with Mycobacterium tuberculosis .

  • Antiviral Favipiravir Successfully Treats Lassa Virus in Guinea Pigs

    October 13, 2015

    Favipiravir, an investigational antiviral drug currently being tested in West Africa as a treatment for Ebola virus disease, effectively treated Lassa virus infection in guinea pigs, according to a new study from National Institutes of Health (NIH) scientists and colleagues.

  • NIH Scientists Identify How Normally Protective Immune Responses Kill Neurons

    October 6, 2015

    National Institutes of Health scientists studying inflammation of the brain have discovered why certain immune responses, which typically help cells recognize and fight viral and bacterial infections, can sometimes be harmful to the brain.

September 2015

August 2015

  • NIH Launches Human RSV Study

    August 26, 2015

    ​A new study will expose healthy adult volunteers to respiratory syncytial virus (RSV). Better understanding of how adults develop RSV infection and immune system responses to infection will help researchersdevelop and test future antivirals and vaccines to combat the virus. 

  • NIH Scientists and Colleagues Successfully Test MERS Vaccine in Monkeys and Camels

    August 19, 2015

    ​National Institutes of Health scientists and colleagues report that an experimental vaccine given six weeks before exposure to Middle East respiratory syndrome coronavirus (MERS-CoV) fully protects rhesus macaques from disease.

  • NIH-Developed Epstein-Barr Virus Vaccine Elicits Potent Neutralizing Antibodies in Animals

    August 13, 2015

    National Institute of Allergy and Infectious Diseases researchers and their collaborators have developed an experimental, nanoparticle-based vaccine against Epstein-Barr virus that can induce potent neutralizing antibodies in vaccinated mice and nonhuman primates.

  • NIH-Funded Study Establishes Genomic Data Set on Lassa Virus

    August 13, 2015

    An international team of researchers has developed the largest genomic data set in the world on Lassa virus. The new genomic catalog contains viral genomes collected from patient samples in Sierra Leone and Nigeria, as well as field samples from the major animal reservoir of Lassa virus-the rodent Mastomys natalensis. 

  • Single Dose Ebola Vaccine is Safe and Effective in Monkeys against Outbreak Strain

    August 6, 2015

    National Institutes of Health scientists report that a single dose of an experimental Ebola virus (EBOV) vaccine completely protects cynomolgus macaques against the current EBOV outbreak strain when given at least 7 days before exposure, and partially protects them if given 3 days prior.

July 2015

  • HVTN 505 Vaccine Induced Antibodies Nonspecific for HIV

    July 30, 2015

    A study by researchers helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection despite robustly inducing anti-HIV antibodies: the vaccine stimulated antibodies that recognized HIV as well as microbes commonly found in the intestinal tract. 

  • Experimental MERS Vaccine Shows Promise in Animal Studies

    July 28, 2015

    A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. 

  • Two Paths Pave Way for Development of a Preventive HIV Vaccine

    July 23, 2015

    National Institute of Allergy and Infectious Diseases& scientists offer a historical perspective on the search for a safe, effective HIV vaccine and describe how they influence current promising approaches in HIV vaccinology.

  • Study Finds PrEP Use Feasible Among High-Risk Groups in U.S. Community Settings

    July 21, 2015

    ​A majority of men who have sex with men and transgender women at high risk for HIV infection took anti-HIV medication for pre-exposure prophylaxis (PrEP), most of the time, in a multi-site U.S. study ( PrEP Demo Project) examining use of this HIV prevention strategy outside of a clinical trial. 

  • Virus-Like Particle Vaccine Protects Mice from Many Flu Strains

    July 21, 2015

    Researchers from the National Institute of Allergy and Infectious Diseases have devised a way to induce protective immunity in mice against a wide array of influenza viruses.

  • HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus

    July 20, 2015

    ​Antiretroviral treatment that consistently suppresses HIV is highly effective at preventing sexual transmission of the virus in heterosexual couples where one person is HIV-infected and the other is not, investigators report. ​

  • Young South African Women Can Adhere to Daily PrEP Regimen as HIV Prevention, Study Finds

    July 20, 2015

    A clinical study funded by the National Institutes of Health has found that young, single black women in South Africa adhered to a daily pill regimen to prevent HIV infection-an HIV prevention strategy known as pre-exposure prophylaxis, or PrEP. 

  • Alefacept Helps Preserve Function of Insulin-Producing Cells in Type 1 Diabetes

    July 20, 2015

    ​Results from a clinical trial sponsored by the National Institute of Allergy and Infectious Diseases suggest that the immune-suppressing drug alefacept helps preserve function of insulin-producing beta cells in people with newly diagnosed Type 1 diabetes.

  • Dr. Fauci at IAS 2015

    July 20, 2015

    Although much progress has been made in combating the global HIV/AIDS pandemic, to halt new infections and end the pandemic, a combination of non-vaccine and vaccine prevention modalities will be needed, says Anthony S. Fauci, M.D.. 

  • Early Antiretroviral Therapy Prevents Non-Aids Outcomes in HIV-Infected People, NIH-Supported Study Finds

    July 20, 2015

    Starting antiretroviral therapy early not only prevents serious AIDS-related diseases, but also prevents the onset of cancer, cardiovascular disease, and other non-AIDS-related diseases in HIV-infected people, according to a new analysis of data from the Strategic Timing of AntiRetroviral Treatment study.

  • Cholesterol Metabolism in Immune Cells Linked to HIV Progression

    July 17, 2015

    Lower levels of cholesterol in certain immune cells-a result of enhanced cholesterol metabolism within those cells-may help explain why some HIV-infected people are able to naturally control disease progression..

  • Investigational Aerosolized Ebola Vaccine Shows Promise in Nonhuman Primates

    July 13, 2015

    ​​An experimental aerosolized (inhalable) vaccine fully protected nonhuman primates against Ebola virus disease. Aerosolized vaccines are delivered using a nebulizer, a device that transforms liquid into a mist that can be inhaled into the lungs.

  • NIH-Funded Vaccine for West Nile Virus Enters Human Clinical Trials

    July 6, 2015

    ​A clinical trial of a new investigational vaccine designed to protect against West Nile Virus infection will be sponsored by the National Institute of Allergy and Infectious Disease.

June 2015

May 2015

  • Starting Antiretroviral Treatment Early Improves Outcomes for HIV-Infected Individuals

    May 27, 2015

    ​Scientists from the National Institute of Allergy and Infectious Diseases and colleagues have identified 80 currently licensed drugs that demonstrated antiviral activity against Zaire ebolavirus in laboratory testing. 

  • HIV Reservoirs Remain Obstacles to Cure

    May 19, 2015

    Antiretroviral therapy (ART) has proven lifesaving for people infected with HIV; however, the medications are a lifelong necessity for most HIV-infected individuals and present practical, logistical, economic and health-related challenges. 

  • HIV Vaccine Awareness Day 2015

    May 18, 2015

    ​Vaccination has historically been the best method for protecting against and ultimately defeating mankind's most devastating infectious diseases. Although the path to developing a safe and effective HIV vaccine has so far been difficult, achieving this goal remains key to realizing a durable end to the global HIV/AIDS pandemic. 

  • NYVAC-HIV Vaccine Used in the HVTN 092 and HVTN 096 Clinical Trials

    May 13, 2015

    ​The National Institute of Allergy and Infectious Diseases  has learned that NYVAC-HIV, an investigational HIV vaccine previously administered in two small HIV vaccine studies, was contaminated with a bacterium called Mycoplasma hyorhinis.

  • NIAID Recognizes Significant Milestone in Ebola Vaccine Study

    May 7, 2015

    In partnership with the Liberian Ministry of Health, the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health is pleased to announce the successful enrollment of all 1,500 planned participants in the Phase 2 portion of the Ebola vaccine clinical trial known as PREVAIL (Partnership for Research on Ebola Vaccines in Liberia).

  • Mobile Phone Microscope Rapidly Detects Parasite Levels in Blood

    May 6, 2015

    Scientists from the National Institute of Allergy and Infectious Diseases and the University of California, Berkeley, and colleagues have developed a mobile phone microscope to measure blood levels of the parasitic filarial worm Loa loa. 

  • NIH Statement on World Asthma Day 2015

    May 5, 2015

    On World Asthma Day 2015, the National Institutes of Health stands with the international community to renew our commitment to advance our understanding of asthma and develop effective strategies to manage and prevent the disease.

April 2015

  • World Malaria Day 2015

    April 25, 2015

    On World Malaria Day 2015, the National Institutes of Health reaffirms its longstanding commitment to reducing the global burden of this devastating and persistent disease. 

  • NIH-Funded Research Leads to Approval of Drug for Acute Radiation Injury

    April 21, 2015

    ​The Food and Drug Administration has approved the use of filgrastim (trade name Neupogen) to increase survival of people acutely exposed to high doses of radiation that damage the bone marrow, for example, as a result of a nuclear power plant accident or terrorist attack. 

  • NIH Launches Largest Clinical Trial Focused on HIV-Related Cardiovascular Disease

    April 15, 2015

    Researchers have begun enrolling participants in a multicenter international clinical trial to test whether statin administration can reduce the risk for major adverse cardiovascular events, such as heart attacks, strokes, and heart disease, in people with HIV infection. 

  • NIH, South African Medical Research Council Award $8 Million in HIV, TB Grants

    April 13, 2015

    ​The National Institutes of Health and the South African Medical Research Council are awarding 31 grants to U.S. and South African scientists to support research targeting HIV/AIDS, tuberculosis and HIV-related co-morbidities and cancers.

  • NIH Funds Nine Antimicrobial Resistance Diagnostics Projects

    April 9, 2015

    ​The National Institute of Allergy and Infectious Diseases has awarded more than $11 million in first-year funding for nine research projects supporting enhanced diagnostics to rapidly detect antimicrobial-resistant bacteria. 

  • Anti-HIV Antibody Shows Promise in First Human Study

    April 8, 2015

    A single infusion of an experimental anti-HIV antibody called 3BNC117 resulted in significantly decreased HIV levels that persisted for as long as 28 days in HIV-infected individuals, according to Phase 1 clinical trial findings published online in Nature. 

  • NIH-Funded Scientists Identify Receptor for Asthma-Associated Virus

    April 6, 2015

    ​Scientists funded by the National Institute of Allergy and Infectious Diseases have identified a cellular receptor for rhinovirus C, a cold-causing virus that is strongly associated with severe asthma attacks. 

  • Experimental Ebola Vaccine Safe, Prompts Immune Response

    April 1, 2015

    ​An early-stage clinical trial of an experimental Ebola vaccine conducted at the National Institutes of Health and the Walter Reed Army Institute of Research found that the vaccine, called VSV-ZEBOV, was safe and elicited robust antibody responses in all 40 of the healthy adults who received it.

March 2015

  • Ebola Test Vaccines Appear Safe in Phase 2 Liberian Clinical Trial

    March 26, 2015

    Two experimental Ebola vaccines appear to be safe based on evaluation in more than 600 people in Liberia who participated in the first stage of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase 2/3 clinical trial. 

  • NIH Study Finds No Evidence of Accelerated Ebola Virus Evolution in West Africa

    March 26, 2015

    The Ebola virus in the ongoing West African outbreak appears to be stable-that is, it does not appear to be mutating more rapidly than viruses in previous Ebola outbreaks, and that is reassuring," said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases.

  • NIH Statement on World TB Day 2015

    March 24, 2015

    World TB Day, March 24, marks the day in 1882 when German microbiologist Robert Koch announced his discovery of the bacterium that causes tuberculosis (TB). Despite the considerable progress made since that discovery, TB remains one of the world's deadliest diseases.

  • NIH Researchers Identify Red Blood Cell Traits Associated with Malaria Risk in Children

    March 24, 2015

    Researchers at the National Institute of Allergy and Infectious Diseases have determined that certain red blood cell traits in children can increase or decrease their risk for malaria. The findings could help identify future targets for new malaria drugs and vaccines. 

  • NIH-Funded Researchers Find Off-Patent Antibiotics Effectively Combat MRSA Skin Infections

    March 19, 2015

    Researchers funded by the National Institute of Allergy and Infectious Diseases have found that two common antibiotic treatments work equally well against bacterial skin infections caused by methicillin-resistant Staphylococcus aureus acquired outside of hospital settings.

  • NIH Researchers Develop Database on Healthy Immune System

    March 12, 2015

    ​An extensive database identifying immune traits, such as how immune cell function is regulated at the genetic level in healthy people, is reported by researchers from the National Institutes of Health (NIH) and their collaborators. 

  • NIH-Led Study to Assess Community-Based Hepatitis C Treatment in Washington, D.C.

    March 6, 2015

    National Institutes of Health  launched a clinical trial in Washington, DC, to examine whether primary care physicians and other health care providers can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus infection. 

February 2015

  • Liberia-U.S. Clinical Research Partnership Opens Trial to Test Ebola Treatments

    February 27, 2015

    In partnership with the Liberian government, the National Institute of Allergy and Infectious Diseases launched a clinical trial to obtain safety and efficacy data on the investigational drug ZMapp as a treatment for Ebola virus disease. The study will be conducted in Liberia and the United States. 

  • HIV Controls Its Activity Independent of Host Cells

    February 26, 2015

    ​A major hurdle to curing people of HIV infection is the way the virus hides in a reservoir composed primarily of dormant immune cells. 

  • NIH-Funded Researchers Identify Genetic Region Associated with Peanut Allergy

    February 24, 2015

    Research funded by the National Institutes of Health suggests that changes in a small region of chromosome 6 are risk factors for peanut allergy in U.S. children of European descent.

  • Study Finds Peanut Consumption in Infancy Prevents Peanut Allergy

    February 23, 2015

    ​Introduction of peanut products into the diets of infants at high risk of developing peanut allergy was safe and led to an 81 percent reduction in the subsequent development of the allergy, a clinical trial has found.

  • NIH-Supported Clinical Trials to Evaluate Long-Acting, Injectable Antiretroviral Drugs to Prevent HIV Infection

    February 18, 2015

    ​Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases and conducted by the NIAID-funded HIV Prevention Trials Network.

  • NIH-Sponsored HIV Vaccine Trial Launches in South Africa

    February 18, 2015

    ​A clinical trial called HVTN 100 has been launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in study participants.

  • NIH-Funded Scientists Create Potential Long-Acting HIV Therapeutic

    February 18, 2015

    ​Scientists have created a new molecule that shows promise for controlling HIV without daily antiretroviral drugs. The molecule foils a wider range of HIV strains in the laboratory than any known broadly neutralizing HIV antibody and is more powerful than some of the most potent of these antibodies. 

  • NIH Expands Key Tuberculosis Research Program

    February 18, 2015

    ​The National Institute of Allergy and Infectious Diseases is expanding its Tuberculosis Research Units (TBRU) program in an effort to drive innovation in tuberculosis research. 

  • NIH Ebola Study in Macaques Provides Timeframes for Post-Mortem Viral Stability

    February 12, 2015

    To determine how long Ebola virus could remain infectious in a body after death, National Institutes of Healths cientists sampled deceased Ebola-infected monkeys and discovered the virus remained viable for at least seven days.

  • NIH Researchers Describe Spontaneous Cure of Rare Immune Disease

    February 5, 2015

    A genetic phenomenon called chromothripsis, or "chromosome shattering," may have spontaneously cured the first person to be documented with WHIM syndrome, according to researchers at the National Institutes of Health.

  • Ebola Vaccine Trial Opens in Liberia

    February 2, 2015

    A large clinical trial to assess the safety and efficacy of two experimental vaccines to prevent Ebola virus infection is now open to volunteers in Liberia. The trial is being led by a recently formed Liberia-U.S. clinical research partnership.

January 2015